Please note that this page is meant ONLY for Malaysian Doctors with a valid Medical Registration Number. Thank you.
Conquering Lung Cancer Together - Part 2
Presenters : Hilmi Lockman, Tan Teik Hin, Anand Sachithanandan & Tho Lye Mun
Posted in : Oncology | Family Medicine | Lung Cancer MasterClass
Published date : Oct 1, 2020
CPD Activity (1.0 credit)
Approx. 1 hour to complete
    
About the Course
Malaysia is a Southeast Asian Multi-ethnic country with over 30 million population. The majority are ethnically Malay, with Indians, Chinese and indigenous peoples as minorities1. Lung cancer is one of the most common cancers and accounts for most of the cancer-related deaths in Malaysia2-4. The recent Malaysian National Cancer registry 2012-16 data show 78% of males & 81% of females of lung, trachea and bronchial cancer are diagnosed at stage 45. Lung cancer survival is poorest among all cancers with the 5-year observed survival rate of 9% and relative survival of 11%6. Screening and early diagnosis remain huge unmet needs.  Limited awareness on lung cancer contributes to late stage presentation in most cases. The stigma around lung cancer as a 'self-inflicted' cancer together with fear and anxiety around chemotherapy, radiotherapy and cultural bias of complementary and traditional therapies are additional hurdles7.
The Lung Cancer Network Malaysia (LCNM) and AstraZeneca are leading this digital initiative to focus on educating the primary care physicians on lung cancer.
Learning Objectives
The initiative is based on the theme of "Conquering Lung Cancer Together" and aim to:
  • Increase the awareness of lung cancer in HCPs, (especially general practitioners as patients/public most likely will first presented to them) in order to improve early detection for timely management of lung cancer.
  • Improve the outcome of lung cancer management-to increase the chance of cure of the disease (early stage) and to improve patient's overall survival for advanced stage.
  • Call to action: GP’s are able to detect and refer the suspected cases to the relevant specialty for timely diagnosis and treatment.
This CPD activity is presented by Dr. Hilmi Lockman, Assoc. Prof. Dr Tan Teik Hin, Dr. Anand Sachithanandan and Dr. Tho Lye Mun, and is supported by an educational grant from Astra Zeneca
Instructions
There are 8 modules in this course. Participants must successfully complete all 8 modules to obtain 1 CPD point, that will be credited instantly in your MMA CPD account. 

About the Presenters

Dr. Hilmi Lockman
MB, BCh, BAO(Ireland); LRCPI & LRCSI, MRCP(UK), MRCP(UK) (Respiratory Medicine), CCT(UK)(Internal Medicine & Respiratory Medicine) Dr. Hilmi is currently a Consultant Respiratory & Internal Medicine Physician in Prince Court Medical Centre, KPJ Kajang Specialist Hospital and an Honorary Medical Lecturer with Universiti Sains Islam Malaysia. He graduated from the Royal College of Surgeons in Ireland and completed his training in internal medicine and respiratory medicine in the UK. Prior to returning home he was a locum consultant in Glenfield Hospital in Leicester, UK. He is actively involved in undergraduate medical education and is a committee member of the Malaysian Thoracic Society. His main interests are in the field of lung cancer, pleural disease and interventional diagnostic procedures.
Assoc. Prof. Dr Tan Teik Hin
MBBS, MMed, FANMB, AM. Assoc. Prof. Dr Tan graduated his MBBS from University of Malaya and obtained Master of Medicine (nuclear medicine) from Universiti Sains Malaysia. He pursued his International Fellowship Programme in Seoul National University Hospital; and Radionuclide Therapy training in Peter MacCallum Cancer Centre, Australia. He currently works as a nuclear medicine physician and clinical researcher in Sunway Medical Centre and Sunway University. His practice mainly focuses on oncologic PET-CT imaging in detecting, staging and monitoring response for cancers, and radionuclide therapy in certain cancers (i.e. thyroid, neuroendocrine tumour and prostate cancer). With regards to lung cancer, his interest is on using respiratory gating (4-D) PET-CT in quantifying lung nodule; and monitoring immunotherapy response using FDG PET-CT. He has published more than 15 peer-reviewed journals and has received numerous best paper awards in international conferences. He is a fellow of Asian Board of Nuclear Medicine and a scientific committee member (for nuclear medicine) in Asia Pacific Neuroendocrine Tumour Society.
Dr. Anand Sachithanandan
MB BCh BAO (Dublin), A.F.R.C.S.I., F.R.C.S.I.(C-Th)(UK), A.M., F.I.C.S., F.A.C.S. (USA)
Dr. Anand Sachithanandan graduated from the RCSI medical school in Dublin, Ireland in 1998. He subsequently completed his postgraduate cardiothoracic specialist surgical training at leading hospitals in the UK. He is a British board - certified cardiothoracic surgeon since 2008 and has been practising as an independent consultant since 2010.
Dr. Anand is a Fellow of the International College of Surgeons, American College of Surgeons and the Royal College of Surgeons in Ireland. He is a highly published surgeon with a special interest in thoracic (chest) conditions especially lung cancer. His clinical expertise includes minimally invasive keyhole VATS surgery.
He has been an invited speaker at numerous national and international scientific meetings.Dr. Anand is co-founder and President of Lung Cancer Network Malaysia (LCNM). He is a Clinical Tutor in Thoracic surgery at the Malaysian Board of Cardiothoracic Surgery (MBCTS) and a Adjunct Senior Lecturer in Surgery at Monash University Malaysia. Dr. Anand is currently practising at Sunway Medical Centre and the Subang Jaya Medical Centre.
Dr. Tho Lye Mun
MBBS(Sydney), MRCP(UK), FRCR(UK), PhD (Glasgow), CCT in Clinical Oncology(UK), Fellowship in Molecular Oncology(UK). Dr. Tho Lye Mun read Medicine as a John Crawford Scholar and graduated from the University of Sydney, Australia in 1998. He went on to train and work in the UK, obtaining both internal medicine MRCP (UK) and clinical oncology FRCR (UK) qualifications. He was then awarded a prestigious joint Cancer Research UK and Royal College of Radiologists research fellowship where his research into novel checkpoint inhibitors as anti-cancer therapy led to him being awarded a PhD in molecular oncology from the University of Glasgow. For his work he was also awarded the John Paul Medal and Anne Hollman Medal. After training and working overseas for 23 years, Dr. Tho returned to Malaysia taking up the post of Associate Professor at the University of Malaya and he then subsequently moved into private practice. His passion and commitment to lung cancer has seen him lead many clinical studies in the field, in particular immunotherapy and serve on numerous regional and international advisory bodies and guideline committees. He has also pioneered the use of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) for lung cancer having undergone further training in Korea and the Cleveland Clinic, USA. He is the current Vice President of South East Asian Radiation Oncology Group (SEAROG). He is co-founder and Vice President of Lung Cancer Network Malaysia.